Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2579652 | 1.00 | TSHR (0.61) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL20283628 | 0.98 | TSHR (0.64) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL8214934 | 0.98 | TSHR (0.64) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL16730520 | 0.98 | TSHR (0.64) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL2586098 | 0.98 | TSHR (0.64) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL23132220 | 0.90 | TSHR (0.54) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL132401 | 0.90 | TSHR (0.54) | TSHRLMNAALDH1A1EPHX2PAOX | |
| SCHEMBL13903715 | 0.90 | CA12 (0.59) | TSHRLMNAALDH1A1EPHX2CA12 | |
| SCHEMBL13903720 | 0.90 | CA12 (0.59) | TSHRLMNAALDH1A1EPHX2CA12 | |
| SCHEMBL18641686 | 0.90 | TSHR (0.54) | TSHRLMNAALDH1A1EPHX2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | claimed |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | UNIVERSITY OF WASHINGTON (US) | 2011-11-03 | — | — | US | disclosed |
| US-7744853-B2 | Radiolabeled annexins | PONIARD PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7115248-B2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060029545-A1 | Radiolabeled annexins | NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN | 2006-02-09 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050036948-A1 | Radiolabeled annexins | NEORX CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1486509-A2 | Radiolabeled annexin-galactose cluster conjugates | NEORX CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-0799050-B1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1426062-A2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| EP-0799050-A4 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORP (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998004294-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997046098-A1 | CLUSTER CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0799050-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1996017618-A1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029545-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA2 2516/4885TSHR 679/4885LMNA 3549/4885 |
| US-20050036948-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA2 2516/4885TSHR 679/4885LMNA 3549/4885 |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | ANXA11, ANXA1, ANXA3 | CA2 2516/4885TSHR 679/4885LMNA 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.